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Abstract
Background Endoscopic injection of N-butyl-2-cyanoacry-
late is the current recommended treatment for gastric vari-
ceal bleeding. Despite the extensive worldwide use, there
are still differences related to the technique, safety, and long
term-results. We retrospectively evaluated the efficacy and
safety of cyanoacrylate in patients with gastric variceal
bleeding.
Patients and Methods Between January 1998 and January
2010, 97 patients with gastric variceal bleeding underwent
endoscopic treatment with a mixture of N-butyl-2-cyanoac-
rylate and LipiodolTM. Ninety-one patients had cirrhosis and
6 had non-cirrhotic portal hypertension. Child-Pugh score at
presentation for cirrhotic patients was A–12.1 %; B–53.8 %;
C–34.1 % and median MELD score at admission was 13 (3–
26). Successful hemostasis, rebleeding rate and complica-
tions were reviewed. Median time of follow up was
19 months (0.5–126).
Results A median mixture volume of 1.5 mL (0.6 to 5 mL),
in 1 to 8 injections, was used, with immediate hemostasis
rate of 95.9 % and early rebleeding rate of 14.4 %. One or
more complications occurred in 17.5 % and were associated
with the use of Sengstaken-Blakemore tube before cyano-
acrylate and very early rebleeding (p<0.05). Hospital mor-
tality rate during initial bleeding episode was 9.3 %. Very
early rebleeding was a strong and independent predictor for
in-hospital mortality (p<0.001). Long-term mortality rate
was 58.8 %, in most of the cases secondary to hepatic
failure.
Conclusion N-butyl-2-cyanoacrylate is a rapid, easy and
highly effective modality for immediate hemostasis of gas-
tric variceal bleeding with an acceptable rebleeding rate.
Patients with very early rebleeding are at higher risk of
death.
Keywords Cirrhosis . Hemostasis . Portal hypertension .
Variceal bleeding
Introduction
Over the past two decades, in-hospital mortality of patients
with cirrhosis and variceal bleeding decreased threefold as a
result of new treatment modalities, combined use of phar-
macological and endoscopic therapies, and short-term anti-
biotic prophylaxis. However, the mortality from a first
variceal bleed remains as high as 14.5 % [1]. Although less
common than esophageal varices, gastric varices occur in
approximately 20 % of patients with portal hypertension.
Bleeding from gastric varices is usually more severe and
difficult to control and has a higher mortality than esopha-
geal variceal bleeding. After control of acute bleeding, the
rebleeding rate can be high, depending on the applied en-
doscopic therapeutic modality. Soehendra et al. first
reported in 1986 that bleeding from gastric varices could
be controlled by intravariceal injection of the tissue adhesive
agent butyl cyanoacrylate [2]. Since then, several authors
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have used different sclerosing agents to achieve hemostasis,
but N-butyl-2-cyanoacrylate (Histoacryl™) is the only
promising agent, achieving primary hemostasis in 70 % to
100 % of patients, with an early rebleeding rate ranging
from 0 % to 23 % [3–10]. In fact, although sclerotherapy
with 5 % ethanolamine oleate, absolute ethanol or 1 %
polidocanol has been reported to control bleeding in about
66 % of patients, it has a rebleeding rate of 50 % and it is
more effective in patients with gastroesophageal varices
than with fundal varices [11]. When compared to absolute
ethanol, in a small randomized-controlled trial of patients
with isolated fundal varices, cyanoacrylate was significantly
more effective in achieving variceal obliteration than alco-
hol (100 % vs. 44 %) [12]. Absolute ethanol is also associ-
ated with high incidence of complications, in particular,
gastric ulcerations. Variceal band ligation is currently the
usual therapy for esophageal varices and can also be used
with success for gastroesophageal varices, however with
lower initial hemostatic rate and higher rebleeding rates than
cyanoacrylate [10]. Human thrombin has also been
employed for endoscopic variceal obturation in small stud-
ies, with reported initial hemostasis rate of 92 % and no
rebleeding [13]. Although there is no consensus for the
optimal treatment of gastric varices, N-butyl-2-cyanoacry-
late tissue glue injection is the only treatment that has been
shown to be effective and its use is recommended by
Baveno V consensus workshop [14]. There are still differ-
ences related to the technique, safety and long term results.
Our study was conducted to address the safety and the
results with N-butyl-2-cyanoacrylate injection in acute gas-
tric bleeding varices.
Patients and Methods
Patients Between January 1998 and January 2010, 97
patients were admitted to our facility with acute bleeding
from gastric varices and underwent endoscopic injection of
N-butyl-2-cyanoacrylate (Histoacryl™; B. Braun, Melsun-
gen, Germany) combined with Lipiodol™ (Laboratoire
Guerbert, Aulnay-Sous-Bois, France) for hemostasis. The
mean (±SD) age was 59.6±11.8 years with male patients
accounting for 80 % (n078). Liver cirrhosis was the etiol-
ogy of portal hypertension in 91 patients (93.8 %) and only
6 patients (6.2 %) had non-cirrhotic portal hypertension.
The main etiology of bleeding gastric varices was alcohol
related-cirrhosis in 73 (75.3 %), followed by virus in 10
(10.3 %), alcohol and virus in 4 (4.1 %) and other causes in
4 (4.1 %). In terms of liver cirrhosis disease severity, 11
patients (12.1 %) belonged to Child-Pugh A, 49 (53.8 %) to
Child-Pugh B, and 31 (34.1 %) to Child-Pugh C. Median
MELD score at admission was 13 (range: 3 to 26). Mean
(±SD) hemoglobin level was 8.3±2.1 g/dL and mean
prothrombin rate was 56.1±15 %. Clinical presentation
was with hematemesis (48.5 %), hematemesis and melena
(41.2 %) or melena (10.3 %). Among these patients, 20
(20.6 %) had active bleeding (spurting or oozing) and 77
(79.4 %) high-risk stigmata of recent variceal bleeding,
including red wale spots, adherent clot or a plug (nipple)
sign on a gastric varix in a patient with recent upper GI
bleeding without other potential source of hemorrhage.
Some patients were transferred from outside hospitals. Scle-
rosants were previously unsuccessfully used in 23 patients
(23.7 %) and Sengstaken-Blakemore tube was used for
temporary control of bleeding in 25 (25.8 %). Clinical
characteristics of patients with gastric variceal bleeding are
expressed in Table 1.
The location of gastric varices was determined according
to the classification described by Sarin and divided into
gastroesophageal varices type 1 (GOV1) or gastric varices
continuing as an extension of esophageal varices along the
lesser curve of the stomach, gastroesophageal varices type 2
(GOV2) or gastric varices continuing as an extension of
esophageal varices toward the greater curvature, isolated
gastric varices type 1 (IGV1) or fundal varices within a
Table 1 Clinical characteristics of patients with gastric varices




Etiology of gastric varices
Cirrhosis 91 (93.8 %)
Alcoholism 73 (75.3 %)
Virus 10 (10.3 %)
Alcoholism and virus 4 (4.1 %)
Others 4 (4.1 %)
Non-cirrhotic PHT 6 (6.2 %)
Bleeding status
Active bleeding 20 (20.6 %)
Recent bleeding 77 (79.4 %)
Child-Pugh classification
A 11 (12.1 %)
B 49 (53.8 %)
C 31 (34.1 %)
MELD score 13 (3-26)
Gastric varices classification
GOV1 36 (37.2 %)
GOV2 27 (27.8 %)
IGV1 30 (30.9 %)
IGV2 4 (4.1 %)
PTH portal hypertension; GOV gastroesophageal varices; IGV isolated
gastric varices; MELD model for end-stage liver disease
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few centimeters of the gastric cardia, and isolated gastric
varices type 2 (IGV2) or ectopic varices located in the
antrum, corpus and first duodenal portion.
The study is in accordance with the ethical standards of
institutional ethics committee and with the Helsinki Decla-
ration. Informed consent was obtained from all patients and/
or their relatives for all procedures.
Methods N-butyl-2-cyanoacrylate was mixed with Lipiodol
in a 1:1 or 1:1.5 ratio. Before injection, the dead space
volume of the injection catheter was filled with distilled
water. The Histoacryl-Lipiodol mixture was injected directly
into gastric varices, followed immediately by an injection of
distilled water in the same volume than the dead space to
deliver the entire glue from the catheter into the varix. The
needle was then retracted and washed with distilled water to
flush out any Histoacryl retained in the catheter. The
injected volume of the Histoacryl-Lipiodol mixture was
based on the variceal dimension and appearance. Reinjec-
tion was performed during the same session for persistent
bleeding or incomplete obliteration (soft sensation on pal-
pation with the retracted needle) or during a follow up
session for poor variceal obliteration and contiguous unob-
literated varices. The injection was strictly intravariceal to
avoid ulceration. An X-ray film was taken after each session
to check the presence and contour of the cyanoacrylate cast
or to detect any embolic material in the chest in patients
whom were suspected to have cyanoacrylate embolism. All
patients received intravenous broad spectrum antibiotics
prophylactically and octreotide infusion (50 mcg/h for the
first 48 h and 25 mcg/h in the next 72 h) or terlipressin at
admission and continued for 5 days. The Sengstaken-
Blakemore tube was used, when necessary, for temporary
control of bleeding until the application of the Histoacryl-
Lipiodol mixture, and when hemostasis was not achieved
and patients were directed to other therapies.
Outcome measures Initial hemostasis was defined by the
presence of stable vital signs and the absence of bleed-
ing within 48 h after treatment. Rebleeding was defined
either as active bleeding from treated varices seen dur-
ing endoscopy or occurrence of hematemesis and/or
melena associated with a decrease in hemoglobin of >2 g/dL
or associated with hemodynamic instability. Very early
rebleeding was defined as occurring within 48 to 120 h of
initial hemostasis and early rebleeding was defined as occur-
ring after 120 h and earlier than 6 weeks of initial hemostasis.
The outcome measures were immediate hemostasis rate,
very early and early rebleeding rate, the bleeding mor-
tality rate and procedure-related complications. Compli-
cations included fever, lung effusion, pulmonary
embolism, cerebral infarction, septicemia and aspiration
pneumonia.
Data analysis Statistical interpretation of data was per-
formed using Statistical Package for Social Sciences version
16.0 for Windows (SPSS, Inc., Chicago, Illinois, USA).
Data were expressed as percent, mean±standard deviation,
or median and range as appropriate. Student t test, χ2 test
and Fisher’s exact test were used wherever appropriate to
assess differences between groups with respect to the mor-
tality and complication rates (p<0.05 was considered statis-
tically significant). With the significant prognostic variables
multivariate logistic regression was carried out using for-
ward stepwise (conditional) method to select independent
predictors of mortality.
Results
A total of 97 patients with bleeding gastric varices under-
went endoscopic obliteration with N-butyl-2-cyanoacrylate
injection from January 1998 to January 2010. The mean
transfusion requirement for packed red blood cells during
the index bleeding episode was 4.7±3.6 units. According to
Sarin’s classification of gastric varices, GOV1 were detected
in 36 patients (37.2 %), GOV2 in 27 (27.8 %), IGV1 in 30
(30.9 %) and IGV2 in 4 (4.1 %) (Table 1). Median time from
admission until first cyanoacrylate injection was 24 h
(range: 3 to 360), and a median mixture volume of 1.5 mL
(range: 0.6 to 5 mL) was injected, in 1 to 8 injections per
procedure (median 2).
Treatment efficacy The overall success rate for achieving
initial hemostasis with N-butyl-2-cyanoacrylate was 95.9 %,
without recurrent bleeding within 48 h. Rebleeding occurred
in 14 (14.4 %) patients after 48 h: very early rebleeding in 3
patients (3.1 %) and early rebleeding in 11 patients (11.3 %).
Primary hemostasis failure and rebleeding were statistically
independent of hepatic function and sub-types of gastric
varices. However there were no rebleeding or primary he-
mostasis failure in IGV2 and non-cirrhotic portal hyperten-
sion. Secondary hemostasis with cyanoacrylate was applied
in 8 (44.4 %) patients with no initial hemostasis or with
rebleeding.
In-hospital mortality rate was 9.3 %. Factors associated
with in-hospital mortality (p<0.05) were: poor hepatic func-
tion (Child-Pugh C), no immediate hemostasis with cyano-
acrylate, need for Sengstaken-Blakemore tube after
cyanoacrylate, presence of complications, very early
rebleeding and prothrombin rate inferior to 42 %. Multivar-
iate logistic regression with the significant prognostic vari-
ables (Child-Pugh class was excluded from analysis as some
patients had a non-cirrhotic portal hypertension; need for
Sengstaken-Blakemore tube after cyanoacrylate was also
excluded because these patients were the same as those that
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did not achieve immediate hemostasis with cyanoacrylate)
selected very early rebleeding as the strongest independent
predictor for in-hospital mortality (p<0.001).
Follow up During the follow up period (median 19 months,
range 0.5–126 months) 35 % of the patients presented new
episodes of GI bleeding, mostly from esophageal varices.
Reinjection with cyanoacrylate for poor gastric variceal
obliteration or contiguous unobliterated gastric varices
detected in a follow up session was performed in 12
(12.4 %) patients. Overall mortality rate was 58.8 %, result-
ing in most of the cases from hepatic failure deterioration. It
was associated with class C of Child-Pugh classification in
cirrhotic patients (p00.05).
Complications Complications of the procedure occurred in
17 patients (17.5 %), including pyrexia (>38°C) in 14.4 %,
pulmonary embolism in 5.2 % and cerebral embolism in
3.1 %. The factors associated with complications were the
need for Sengstaken-Blakemore tube before cyanoacrylate
and very early rebleeding (p<0.05).
Discussion
Approximately 20 % to 30 % of cirrhotic patients will
experience variceal bleeding within 2 years after diagnosis.
In 10 % to 20 % of the cases the source is from gastric
varices, with a higher bleeding incidence for fundal varices.
Contrasting to esophageal varices, gastric varices represent a
particular therapeutic challenge because of their size and
location, more severe course, and worse outcomes. In addi-
tion to the endoscopic criteria (size of the largest varix and
presence of red-spots), poor hepatic function is the most
important factor predicting hemorrhage from gastric varices
[15]. Because of its excellent efficacy, N-butyl-2-cyanoac-
rylate is considered to be the optimal endoscopic therapy for
gastric variceal bleeding [14]. Indeed, a large number of
case series have demonstrated that N-butyl-2-cyanoacrylate
injection successfully controlled acute gastric varices, with
overall success rates ranging between 70 % to 100 %
[3–10]. Radiologic transjugular intrahepatic portosystemic
shunt (TIPS) placement has also been used as a therapeutic
modality in this setting. However, endoscopic cyanoacrylate
is safe and as clinically effective as TIPS, with a lower rate
of long-term morbidity and much lower cost [16].
Despite the extensive worldwide use of cyanoacrylate,
there are still differences related to the technique, safety and
long-term results. Our study was conducted to address these
issues of safety and efficacy. Ninety-seven patients with
bleeding gastric varices were treated endoscopically with
intravariceal injection of N-butyl-2-cyanoacrylate. At the
time of endoscopy most of patients 77 (79.4 %) had only
stigmata of recent variceal bleeding. This may be due to the
effect of vasoactive drugs (octreotide or terlipressin) given
to all patients before endoscopy and of the use of temporary
Sengstaken-Blakemore tube before cyanoacrylate.
Hemostatic control was successful in 95.9 % of the
patients, comparable to or better than that in other series.
The excellent results in primary hemostasis with cyanoac-
rylate are the consequence of the immediate occlusion of the
lumen of the varix, pointing out to the need to inject the
mixture near the rupture point. The primary hemostasis was
independent of the type of gastric varices and severity of
hepatic dysfunction. The overall early rebleeding rate was
14.4 %, of which 3.1 % was classified as very early rebleed-
ing and 11.3 % as early rebleeding. Early rebleeding rate
after endoscopic treatment with cyanoacrylate has been
reported to vary between 0 % to 23 %, suggesting that
although acute hemostasis is effective, the risk of rebleeding
should not be neglected. Complete obliteration of the vari-
ces during the initial session or follow up reinjection ses-
sions is essential to achieve complete variceal eradication
and prevent rebleeding.
The rebleeding rate was independent of the type of varix.
It was 19 % in GOV1, 11 % in GOV2, 13 % in IGV1 and
0 % in IGV2. Fundal varices, like GOV2 and IGV1 of Sarin
classification, are known to be associated with a high-flow
vessel originating in gastro-renal, gastrophrenic or cardio-
phrenic shunts, and this distinctive anatomy and physiology
contributes to a more aggressive bleeding potential [17].
Kind et al. reported similar rebleeding rates among GOV1
(19.6 %) and GOV2 (18.9 %) varices but higher rebleeding
rate in IGV1 (66.5 %) [18]. However, in our series, that was
not verified. Kim et al. also found that a size of the varix
greater than 5 mm and an advanced Child-Pugh class were
associated with a high risk of bleeding [15].
Endoscopic related complications from cyanoacrylate in-
jection are typically minor (fever and abdominal discom-
fort). However, major fatal complications, usually
associated with glue embolism have been described [5,
19]. In our patients, one or more complications related to
cyanoacrylate injection were seen in 17 patients (17.5 %),
most of them with pyrexia (14.4 %) but also including cases
of pulmonary embolism (5.2 %) and cerebral embolism
(3.1 %). The occurrence of systemic embolization with
cyanoacrylate injection has been associated with a large
volume of injection, to the speed of injection and to the
existence of shunts between portal and pulmonary system,
which are common in cirrhotic patients [19]. In our study,
there were no significant differences in the total volume of
injection between patients with or without embolic compli-
cations (1.9 vs. 1.7 mL). The factors associated with occur-
rence of complications (p<0.05) were the need for
Sengstaken-Blakemore tube before cyanoacrylate and very
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early rebleeding. In fact, Sengstaken-Blakemore tube in the
management of acute variceal hemorrhage has been associ-
ated with a greater risk of complications, namely aspiration
pneumonia [20].
In-hospital mortality rate was 9.3 %, which is consistent
with the reported mortality in other studies. Kind et al.
reported that hospital mortality rate was 19.5 %, and it
was associated to liver failure (76 % of cases) and hemor-
rhagic shock (8.8 %) [18]. In our study, factors that were
associated with in-hospital mortality, were: poor hepatic
function (Child-Pugh C), no immediate hemostasis with
cyanoacrylate, need for Sengstaken-Blakemore tube after
cyanoacrylate, presence of complications, very early
rebleeding and prothrombin rate <42 %. Of all these factors,
very early rebleeding (occurring within 48 to 120 h of initial
hemostasis) was the strongest independent predictor for in-
hospital mortality. In fact, mortality reached 28.6 % in the 7
patients with persistent bleeding or with very early rebleed-
ing. The treatment failure-related mortality rate was 2 % (2
of 97). Huang et al. also verify that the mortality due to
rebleeding immediately after cyanoacrylate sclerotherapy
was 12.5 % and treatment failure-related mortality rate was
2.2 % [5].
Overall mortality rate was 58.8 %, comparable to other
series previously reported [3, 5]. Similar to these series,
where the determining factor for long term survival was
the underlying disease leading to portal hypertension, mor-
tality was associated with the degree of the hepatic dysfunc-
tion, namely Child-Pugh class C (p<0.05).
In conclusion, N-butyl-2-cyanoacrylate injection is a rap-
id, low-cost and simple therapeutic option for acute gastric
variceal bleeding. It is highly effective for achieving imme-
diate hemostasis with an acceptable rebleeding rate. As very
early rebleeding predicts in-hospital mortality, complete
variceal obliteration is essential to achieve good outcomes.
Major complications after cyanoacrylate occur but are rare.
Taking in account all these results, N-butyl-2-cyanoacrylate
injection should be the first choice for bleeding gastric
varices.
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